Vigil Neuroscience

News

Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience.

News

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.